Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.
about
A disease spectrum for ITPA variation: advances in biochemical and clinical researchProgress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicityITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV InfectionPharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variantsLimited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir.An index to predict ribavirin-induced anemia in asian patients with chronic genotype 1 hepatitis CVariants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypesRole of genetic polymorphisms in hepatitis C virus chronic infection.Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC StudyAssociation of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis CITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.PharmGKB summary: peginterferon-α pathway.Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection.Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients.Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy.The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean.ITPA (inosine triphosphate pyrophosphatase): from surveillance of nucleotide pools to human disease and pharmacogeneticsIndividualization of chronic hepatitis C treatment according to the host characteristics.Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection.Telaprevir for the treatment of chronic hepatitis C infection.Hepatocellular carcinoma: towards personalized medicine.Host factors determining the efficacy of hepatitis C treatment.Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis.The role of pharmacogenetics in the treatment of chronic hepatitis C infection.Review article: genetic factors that modify the outcome of viral hepatitis.Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels.ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.Efficacy and safety of telaprevir with pegylated interferon α-2a and ribavirin in Japanese patients.Inosine triphosphate pyrophosphohydrolase activity: more accurate predictor for ribavirin-induced anemia in hepatitis C infected patients than ITPA genotype.Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b.SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir.Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan.Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C.Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.Distribution of genetic polymorphisms associated with hepatitis C virus (HCV) antiviral response in a multiethnic and admixed population.ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.
P2860
Q28069352-3AAE4EB2-425D-4267-88A1-0FA7127D98A0Q28083100-2ED05120-D115-47D8-A8ED-2AC067902D9BQ28606732-C4FFDA7E-DB99-46EE-A63D-BE91DF84D621Q33404251-405C851E-C6C1-48E9-876F-C5A46E5B8E19Q35156156-F267AB56-DAAE-4146-9293-E0F8F38D569EQ35226233-EFD41A68-4531-4D20-B795-7713B2097F2FQ35768047-9629575A-152D-4F4C-B1FD-84823930441BQ35779058-8F35358E-ACD1-474E-AA57-71E6D47F26CCQ35869247-E702D559-7A0E-4EEB-8A40-C3314AA2B764Q36018931-AF540ED3-B8A0-4B7B-BEB9-C625308E1DACQ36059685-A2747D68-D74D-45B5-A631-2374C327DBD7Q36457789-4EB9067A-366B-4C19-BCA1-DC4FE0F1CCBFQ36590755-380F05D6-FCBC-43CE-AE2C-FBB29FC1D754Q36645372-07E7A75D-AEA9-4FE6-B8C4-0EF3EACB28C3Q36699265-2436BCA4-5928-4EEC-9921-01E8F239BB8FQ37060571-8174FBB9-42FC-4628-B2CA-2EFAA6748357Q37098107-B71D4BFA-F57D-4C1D-94E0-2D4691CB7285Q37308142-74327BD4-FCFB-4174-8CBE-47D4F0B48BD7Q37654502-FF0E676A-0D11-48D5-B4AF-C02EA28EE7B2Q37678718-7BDAB5C4-6399-41BA-BEBE-3E9C57C83F44Q37879701-45065472-0DAB-4448-97BB-34D3D6F864ABQ37960561-7B169003-0524-4BE3-8901-7E4A0063AB29Q37984653-B49DEB74-2404-4488-90CB-0931FAF3E01EQ38056077-33C5BB86-2989-4B2D-A16B-E2E62F5D1B2AQ38093509-4778D056-AB00-4BE1-B5F6-401638CC4E13Q38151586-51164F45-641E-4245-9AC9-67E6669295BAQ38198089-943F7E9B-01FF-4B3F-A6FE-0F4F58D81701Q40155391-F5797BAC-1CC0-41E8-A9AB-C6789A05074CQ40363387-6C38180D-F7B8-4340-A9D1-D8609F52D9C2Q40385212-D7DC04CD-3F3F-41ED-8D76-5B8C326466BBQ40460374-235823FD-2B8B-4C12-9C07-6B2D08DC80C4Q40721350-70784E8E-5ED2-4175-9106-7908BD03AC43Q41236221-F9615022-CF39-4E07-AF06-6D844126BE75Q41473188-012E73AB-7D66-49FB-A339-D58B2F4CB532Q41547430-B4382A79-7B73-472D-867C-1F42DA248195Q41750322-BB29FF8B-403B-4AC6-A7A6-79D5D88E762AQ42202049-482E372F-0F1A-463C-87C9-965C1E12543CQ42212457-05D0EED3-995E-4F44-B3DC-F0FFAEBC2053Q42217800-64D81040-DBA3-48D8-A628-8EAB2033AAE9Q42223359-764D406B-41E9-414B-8D62-AA728E44D832
P2860
Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Influence of ITPA polymorphism ...... on, ribavirin, and telaprevir.
@en
Influence of ITPA polymorphism ...... on, ribavirin, and telaprevir.
@nl
type
label
Influence of ITPA polymorphism ...... on, ribavirin, and telaprevir.
@en
Influence of ITPA polymorphism ...... on, ribavirin, and telaprevir.
@nl
prefLabel
Influence of ITPA polymorphism ...... on, ribavirin, and telaprevir.
@en
Influence of ITPA polymorphism ...... on, ribavirin, and telaprevir.
@nl
P2093
P2860
P356
P1433
P1476
Influence of ITPA polymorphism ...... ron, ribavirin, and telaprevir
@en
P2093
Fumitaka Suzuki
Hiromitsu Kumada
Hitomi Sezaki
Kazuaki Chayama
Kenji Ikeda
Mariko Kobayashi
Masahiro Kobayashi
Miharu Hirakawa
Naoyuki Kamatani
Norio Akuta
P2860
P304
P356
10.1002/HEP.24058
P407
P577
2011-01-18T00:00:00Z